A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 29, 2009, Pages 3625-3630

  Lankheet, A G ^a   Hillebrand, M J X ^a   Langenberg, M H G ^b   Rosing, H ^a   Huitema, A D R ^a   Voest, E E ^b   Schellens, J H M ^a,c   Beijnen, J H ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Beta Faculty   (Netherlands)

Author keywords

Liquid chromatography; Mass spectrometry; Vatalanib

Indexed keywords

ANALYTICAL COLUMNS; ELECTROSPRAY IONIZATION TANDEM MASS SPECTROMETRY; IMATINIB; INTERNAL STANDARDS; ISOTOPICALLY LABELED; LINEAR GRADIENTS; LINEAR RANGE; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LOWER LIMIT OF QUANTIFICATIONS; MULTIPLE-REACTION MONITORING MODES; PHASE I; PLASMA PROTEIN; QUANTITATIVE ANALYSIS; SOLID TUMORS; TANDEM MASS SPECTROMETRY; TRIPLE-QUADRUPOLE MASS SPECTROMETER; VALIDATION STUDY;

CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; ELECTROSPRAY IONIZATION; LIQUIDS; MASS SPECTROMETERS; MASS SPECTROMETRY; PLASMAS;

HIGH PRESSURE LIQUID CHROMATOGRAPHY;

CARBON; DEUTERIUM; IMATINIB; ISOTOPE; PLASMA PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; VATALANIB;

ACCURACY; ARTICLE; ASSAY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MASS SPECTROMETRY; PHASE 1 CLINICAL TRIAL; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLID TUMOR; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CHROMATOGRAPHY, LIQUID; HUMANS; MOLECULAR STRUCTURE; PHTHALAZINES; PYRIDINES; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 72049083755     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.09.001     Document Type: Article

References (11)

1. Moreira I.S., Fernandes P.A., and Ramos M.J. Anticancer Agents Med. Chem. 7 (2007) 223
2. Senger D.R., Van de W.L., Brown L.F., Nagy J.A., Yeo K.T., Yeo T.K., Berse B., Jackman R.W., Dvorak A.M., and Dvorak H.F. Cancer Metastasis Rev. 12 (1993) 303
3. Wood J.M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., Hofmann F., Mestan J., Mett H., O'Reilly T., Persohn E., Rosel J., Schnell C., Stover D., Theuer A., Towbin H., Wenger F., Woods-Cook K., Menrad A., Siemeister G., Schirner M., Thierauch K.H., Schneider M.R., Drevs J., Martiny-Baron G., and Totzke F. Cancer Res. 60 (2000) 2178
4. Jost L.M., Gschwind H.P., Jalava T., Wang Y., Guenther C., Souppart C., Rottmann A., Denner K., Waldmeier F., Gross G., Masson E., and Laurent D. Drug Metab. Dispos. 34 (2006) 1817
5. Stokvis E., Rosing H., and Beijnen J.H. Mass Spectrom. Rev. 24 (2005) 887
6. Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., Horsfield M.A., Mross K., Ball H.A., Lee L., Mietlowski W., Fuxuis S., Unger C., O'Byrne K., Henry A., Cherryman G.R., Laurent D., Dugan M., Marme D., and Steward W.P. J. Clin. Oncol. 21 (2003) 3955
7. Mross K., Drevs J., Muller M., Medinger M., Marme D., Hennig J., Morgan B., Lebwohl D., Masson E., Ho Y.Y., Gunther C., Laurent D., and Unger C. Eur. J. Cancer 41 (2005) 1291
8. U.S. Food and Drug Administration: Centre for Drug Evaluation and Research. Guidance for Industry: Bioanalytical Method Validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (accessed 1.5.01).
9. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., and Weiner R. Pharm. Res. 24 (2007) 1962
10. Stokvis E., Rosing H., Lopez-Lazaro L., Rodriguez I., Jimeno J.M., Supko J.G., Schellens J.H., and Beijnen J.H. J. Mass Spectrom. 37 (2002) 992
11. Langenberg M.H., Witteveen P.O., and Lankheet A.G. J. Clin. Oncol. 27 (2009) (Suppl; abstr. 2575)